Figure 4

NPY application together with its Y2-receptor antagonist BIIE0246 has no effect on epileptiform activity. (a) Example recordings from dentate granule cells during epileptiform activity triggered by 0Mg²⁺/4-AP aCSF. Whole-cell recordings in current-clamp mode, arrows indicate the PDSs that are displayed in zoomed-in time-scale to the right of each sweep. NPY applied together with the Y2 receptor antagonist BIIE0246; under these conditions a reduction in AP or PDS frequency is not observed. (b–d) The average values (±SEM) are displayed in orange, the individual values – in grey. (b) The number of PDS is unchanged during the application of NPY + BIIE0246 (baseline: 35.75 ± 12.33 and NPY + BIIE0246: 26 ± 12.27, n = 8, t-test, p = 0.0834). (c) The number of APs is unchanged during the application of NPY + BIIE0246 (baseline: 633.6 ± 232.8 and NPY + BIIE0246: 650.4 ± 265.3, n = 9, t-test, p = 0.874). (d) The number of APs during the individual PDSs is unchanged during the application of NPY + BIIE0246 (baseline: 4.674 ± 1.028 and NPY + BIIE0246: 5.873 ± 1.361, n = 7, t-test, p = 0.094). (e) Cumulative plot of the time-interval between APs during the baseline recordings (black) and recordings during NPY + BIIE0246 application (blue). No difference between baseline and NPY + BIIE0246 (p = 0.2743, D = 0.0794) was detected with the Kolmogorov-Smirnov test.